Carlsbad, Calif., Jan. 28, 2008 - Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BMG  LABTECH Inc. are entering into a collaboration agreement to validate the compatibility of Invitrogen’s reagents with BMG LABTECH’s microplate detection instruments.

Invitrogen’s drug discovery products will be tested on certain BMG LABTECH microplate readers, and select BMG LABTECH instruments, such as the PHERAstar and OMEGA series, will be certified for use with specific Invitrogen technology platforms.  Initial certifications will focus on Invitrogen’s assay systems for key target classes, such as LanthaScreen™ TR-FRET for protein kinases, PolarScreen™ FP technology for nuclear receptors, GeneBLAzer® reporter-gene technology for G protein-coupled receptors and Adapta™, a new TR-FRET assay system for lipid kinases. This collaboration will allow BMG LABTECH and Invitrogen to develop and promote joint applications for the drug discovery market.

“Through this partnership, researchers will be able to obtain integrated instrumentation and reagent solutions, thereby removing the frustration of discovering that the biological assay system they have chosen is not compatible with the instrumentation and visa versa,” said John Printen, director of Invitrogen’s Cell Signaling business segment.  “This is critical for reaching customers across pharmaceutical research, biotech, academics and government where those scientists are seeking a higher throughput solution for their discovery workflows.”

“BMG LABTECH has a strong installed customer base in both the pharmaceutical sector and the academic research market.  Our customers in both market segments demand high performance instrumentation and assay systems.” says Dr. Ronald Earp, President of BMG LABTECH Inc.   “This partnership will insure that their BMG LABTECH microplate readers will provide optimal performance on Invitrogen assay technologies and allow us to proactively develop instrumentation for future platforms.”

For more information, visit www.invitrogen.com/drugdiscovery. 

About Invitrogen

Invitrogen Corporation (NASDAQ: IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition.  The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction.  Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world.  Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world.  The company employs approximately 4,700 scientists and other professionals and had revenues of more than $1.15 billion in 2006.  For more information, visit www.invitrogen.com.

About BMG LABTECH Inc.
BMG LABTECH Inc. is a privately held daughter company of BMG LABTECH GmbH headquartered in Offenburg Germany.  BMG LABTECH GmbH is solely focused on microplate reader design and manufacturing. BMG LABTECH instrumentation is used in all aspects of life science research, drug discovery efforts, and is extremely well represented in laboratories around the globe.  For more information please visit www.bmglabtech.com.   

Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to 1) Invitrogen’s drug discovery products will be tested on certain BMG LABTECH microplate readers; 2) select BMG LABTECH instruments, such as the PHERAstar and OMEGA series, will be certified for use with specific Invitrogen technology platforms; 3) Initial certifications will focus on Invitrogen’s assay systems for key target classes, such as LanthaScreen™ TR-FRET, PolarScreen™ FP, GeneBLAzer® , and Adapta™; 4) through this partnership, researchers will be able to obtain integrated instrumentation and reagent solutions.  Potential risks and uncertainties include, but are not limited to; a) the agreement may or may not validate the compatibility of Invitrogen’s reagents with BMG LABTECH’s microplate detection instruments; b) this collaboration may or may not allow BMG LABTECH and Invitrogen to develop and promote joint applications for the drug discovery market; c) this partnership may or may not insure that BMG LABTECH microplate readers will provide optimal performance on Invitrogen assay technologies and allow for proactive development of instrumentation for future platforms; and the risks that the market will not accept the companies’ products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.

Media Contact:
Invitrogen Corporation, Revelle Anderson, (760) 268-7482, revelle.anderson@invitrogen.com